Kaposi Sarcoma Clinical Trial
Official title:
A Phase 2 Trial of Ixazomib for Kaposi Sarcoma
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVE: I. Determine the overall response rate of ixazomib in participants with Kaposi sarcoma. SECONDARY OBJECTIVES: I. Determine safety and tolerability of ixazomib. II. Assess changes in Kaposi-sarcoma associated herpesvirus (KSHV) viral load (VL) by ixazomib. III. Correlate changes in KSHV VL with tumor response. IV. For human immunodeficiency virus (HIV)-positive participants, assess changes in CD4 counts and HIV viral load. EXPLORATORY OBJECTIVE: I. Assess changes in quality of life during ixazomib therapy. OUTLINE: Patients receive ixazomib orally (PO) on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks, then periodically for up to 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06445166 -
Propranolol for the Treatment of Kaposi Sarcoma in Adults
|
Phase 2 | |
| Recruiting |
NCT04941274 -
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03160183 -
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
|
||
| Recruiting |
NCT03993106 -
A Study of sEphB4-HSA in Kaposi Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
| Completed |
NCT00395278 -
Development of Serologic Assays for Human Herpes Virus-8
|
||
| Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT03296553 -
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
|
Phase 2 | |
| Completed |
NCT03316274 -
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
|
Early Phase 1 | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Terminated |
NCT04893018 -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
|
Phase 1 | |
| Recruiting |
NCT06375122 -
Natural History Study of Kaposi Sarcoma
|
||
| Recruiting |
NCT05663502 -
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
|
||
| Recruiting |
NCT05329792 -
L19IL2/L19TNF in Skin Cancer Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05411237 -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
|
Phase 3 | |
| Completed |
NCT03050788 -
Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma
|
N/A | |
| Completed |
NCT03404297 -
Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya
|
N/A | |
| Terminated |
NCT01412515 -
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06004011 -
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
|
N/A | |
| Withdrawn |
NCT02229981 -
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
|
Phase 1/Phase 2 |